Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today at the ASX Small and Mid-Cap Conference 2020, a virtual conference.
Steven Lydeamore, Chief Executive Officer, Anatara Lifesciences (ASX:ANR) will be presenting at the ASX Small and Mid-Cap Conference 2020.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30 June 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide an update on initiation of challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf).
While focussing financial resources on development of GaRP, Anatara has been evaluating development, in collaboration with third parties, additional dosage forms for piglets and to utilise Anatara's intellectual property in other species including in-feed formulations for piglets, formulations for aquaculture and formulations for poultry.
Anatara is nearing conclusion of a process of due diligence and negotiation with many of the world's leading animal health companies. Anatara's objective being to partner with a company or companies to register Detach(R) in key overseas markets.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st March 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.3m.
Anatara Lifesciences Ltd (ASX:ANR) provides an update on the impact to the Company of the COVID-19 pandemic.
Anatara Lifesciences Ltd (ASX:ANR) present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the half-year ended 31 December 2019.
Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore was recently interviewed by Stockhead, for its "90 Seconds With" interview series. Steve provided an overview of the Company's key milestones for the next 12 months.
